Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Debt (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Total Debt for 9 consecutive years, with $28.3 million as the latest value for Q4 2023.

  • Quarterly Total Debt rose 7.79% to $28.3 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $28.3 million through Dec 2023, up 7.79% year-over-year, with the annual reading at $28.3 million for FY2023, 7.79% up from the prior year.
  • Total Debt for Q4 2023 was $28.3 million at Cartesian Therapeutics, up from $24.0 million in the prior quarter.
  • The five-year high for Total Debt was $28.3 million in Q4 2023, with the low at $14.8 million in Q2 2020.
  • Average Total Debt over 5 years is $23.6 million, with a median of $25.0 million recorded in 2021.
  • The sharpest move saw Total Debt crashed 31.16% in 2020, then skyrocketed 70.04% in 2021.
  • Over 5 years, Total Debt stood at $18.9 million in 2019, then skyrocketed by 31.15% to $24.8 million in 2020, then increased by 3.39% to $25.6 million in 2021, then grew by 2.45% to $26.3 million in 2022, then grew by 7.79% to $28.3 million in 2023.
  • According to Business Quant data, Total Debt over the past three periods came in at $28.3 million, $24.0 million, and $26.4 million for Q4 2023, Q2 2023, and Q1 2023 respectively.